SABCS

Low ctDNA Levels May Show Longer Recurrence-Free Interval in Breast Cancer

December 31st 2024, 8:00pm

Article

In patients with triple-negative breast cancer, ctDNA was most commonly identified within six months after treatment, reflecting the disease’s typical pattern of early recurrence.

Top 5 Stories from the 2024 San Antonio Breast Cancer Symposium

December 26th 2024, 4:00pm

Article

CURE® highlights some of the top stories from SABCS, including those focused on older and younger patients with breast cancer, in addition to treatment strategies.

Enhertu May Help Preserve Quality of Life in HER2-Positive Breast Cancer

December 19th 2024, 10:00pm

Article

Treatment with Enhertu showed favorable outcomes regarding health-related quality of life in patients with HER2-positive breast cancer, regardless of brain metastases.

Targeting Multiple Pathways Improves Outcomes in Some With Metastatic Breast Cancer

December 19th 2024, 8:00pm

Video

Targeting the estrogen receptor and HER2 pathways improved progression-free survival in patients with HR-positive, HER2-positive metastatic breast cancer.

Surgical Intervention May Improve Survival in Young Patients with Breast Cancer

December 17th 2024, 10:00pm

Article

Younger patients with breast cancer and the BRCA gene showed improved survival after undergoing risk-reducing mastectomy and/or risk-reducing salpingo-oophorectomy.

Camrelizumab Plus Chemo May Be New Presurgical Option in Breast Cancer Subset

December 16th 2024, 2:00pm

Article

Presurgical camrelizumab plus chemotherapy significantly improved responses versus chemotherapy alone in early or locally advanced TNBC.

Tecentriq Regimen Misses End Goal in Triple-Negative Breast Cancer

December 13th 2024, 9:37pm

Article

Tecentriq plus chemotherapy did not improve event-free survival in triple-negative breast cancer but increased rate of complete tumor removal.

HER3-DXd With or Without Femara Effective for Some With High-Risk Breast Cancer

December 13th 2024, 3:00pm

Article

Patients with high-risk, HR-positive, HER2-negative breast cancer treated with HER3-DXd with or without Femara (letrozole) experienced fewer side effects than with chemotherapy.

Understanding Genetics May Predict Treatment Response in Triple-Negative Breast Cancer

December 13th 2024, 2:00pm

Article

Several biomarkers may predict improved treatment responses and outcomes in patients with triple-negative breast cancer.

Postoperative Radiation Offers Higher Quality of Life, Fewer Side Effects in Some with Breast Cancer

December 12th 2024, 10:00pm

Article

Radiation therapy resulted in improved quality of life and fewer side effects for older patients with stage 1 luminal-like breast cancer than endocrine therapy.